Sees FY23 revenue $1.13B-$1.25B, consensus $1.17B.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALKS:
- Alkermes: Nemvaleukin alfa granted an Innovation Passport by MHRA
- Alkermes price target raised to $28 from $27 at BofA
- Alkermes reports interim award in arbitration proceedings with Janssen
- Piper recommends ‘down market cap’ biotech exposure for 2023
- Alkermes positioned for ‘considerable value creation,’ says Piper Sandler